Hypnotics

Chronic insomnia is not only a shortage of sedation. Sleep timing, conditioned arousal, anxiety, depression, pain, breathing disorders, substances, and daily habits can all keep the problem going. CBT-I targets the patterns that maintain insomnia and has a strong evidence base; sleep medicine is generally reserved for people who cannot access CBT-I, still have symptoms after it, or need a temporary bridge.

Most hypnotic trials lasted weeks to a few months. Some longer studies exist, but long-term real-world evidence is thinner, especially for the newest orexin antagonists. A pill can be genuinely useful without being a cure.

SOURCE · AASM CBT-I EVIDENCE REVIEW   SOURCE · AASM COMBINATION-THERAPY DRAFT

Z-drugs strengthen GABA signaling and quiet brain activity for sleep. All three are Schedule IV controlled substances, and dependence, tolerance, misuse, and withdrawal can occur.

Common effects include next-day sleepiness, dizziness, headache, confusion, memory problems, and impaired balance. Do not take extra doses after waking in the night unless the prescription specifically directs it, and do not drive until you know how the medicine affects you.

SOURCE · TEXAS HHS SEDATIVE-HYPNOTIC REVIEW   SOURCE · ZOLPIDEM LABEL   SOURCE · NCBI ZOLPIDEM SAFETY REPORT

In 2019, the FDA required its most prominent warning for zolpidem, eszopiclone, and zaleplon after reports of sleepwalking, sleep-driving, cooking, and other activity while not fully awake—sometimes followed by serious injury or death and no memory of the event. The FDA identified 66 cases over 26 years, including 46 serious injuries and 20 deaths.

This can happen after one dose, at the lowest recommended dose, and with or without alcohol. Anyone who has previously had a complex sleep behavior with one of these medicines should not use it again. If it happens, stop the medicine and contact the prescriber immediately; seek emergency help for injury.

SOURCE · FDA BOXED WARNING   SOURCE · FDA CASE SUMMARY

Morning grogginess, dizziness on standing, and balance or memory effects can occur with trazodone. A painful erection lasting more than four hours is a rare emergency. Orexin antagonists are newer and have less long-term real-world safety data than older options.

SOURCE · OREXIN ANTAGONIST REVIEW   SOURCE · RAMELTEON REVIEW   SOURCE · LOW-DOSE DOXEPIN REVIEW   SOURCE · TRAZODONE SYSTEMATIC REVIEW

• Driving: next-morning impairment can occur even when someone feels awake. Extended-release zolpidem carries the highest next-morning risk; the FDA reduced recommended zolpidem starting doses in 2013 because women, on average, clear it more slowly.
• Alcohol, opioids, benzodiazepines, sedating antihistamines, muscle relaxants, and other sleep aids: sedation and breathing effects stack. Do not combine them unless the prescriber has reviewed the plan.
• Drug interactions: several Z-drugs and orexin antagonists are affected by CYP3A4 inhibitors or inducers, including some antifungals, antibiotics, seizure medicines, rifampin, St. John’s wort, and grapefruit juice. Ramelteon is especially affected by the CYP1A2 inhibitor fluvoxamine.
• Overdose: extreme sleepiness, inability to wake, slow or shallow breathing, or a limp body means 911 immediately. Stay with the person and tell responders what was taken.
• Storage: keep sleep medicines locked and out of reach of children and teens. Never share a prescription.

SOURCE · FDA ZOLPIDEM DOSE CHANGE REPORT   SOURCE · ZOLPIDEM INTERACTIONS   SOURCE · LEMBOREXANT INTERACTIONS

Stopping: abrupt discontinuation of a Z-drug after prolonged or high-dose use can cause anxiety, sweating, tremor, nausea, panic, delirium, or seizures. Rebound insomnia varies by drug and dose. A gradual, clinician-guided taper—often combined with CBT-I—is safer. Ramelteon and low-dose doxepin have not shown a recognized withdrawal signal in the cited trials.

Older adults: the 2023 AGS Beers Criteria recommend avoiding Z-drugs because they can cause delirium, falls, fractures, emergency visits, hospitalizations, and crashes while offering only minimal average improvement. CBT-I comes first; ramelteon, low-dose doxepin, and orexin antagonists may be relatively lower-risk, though next-day sedation still matters.

Pregnancy and breastfeeding: data are limited across the class. Zolpidem crosses the placenta, and late exposure has been associated with low temperature, low muscle tone, feeding difficulty, respiratory depression, or newborn withdrawal. Human pregnancy data for orexin antagonists are essentially absent. Decisions should be shared with the prescriber and obstetric clinician; non-drug treatment is preferred where feasible.

Sleep apnea and lung disease: sedatives can worsen breathing or blunt the arousal response. Loud snoring, witnessed pauses in breathing, known sleep apnea, COPD, or other respiratory illness belongs in the prescriber conversation before a nightly sedative is started.

SOURCE · ZOLPIDEM WITHDRAWAL CASE REPORT   SOURCE · 2023 AGS BEERS CRITERIA   SOURCE · ZOLPIDEM PREGNANCY LABEL   SOURCE · OREXIN REVIEW

Insomnia and depression often overlap, and a sleep medicine does not treat suicidal thinking. New or worsening depression, agitation, unusual behavior, or talk of self-harm needs prompt help. In the United States, call or text 988 for the Suicide & Crisis Lifeline. For an overdose, dangerous breathing, or injury during a complex sleep behavior, call 911 first.

There is no universally safest sleep medicine. The best choice depends on whether the problem is falling asleep, staying asleep, or waking early; age; breathing and fall risk; pregnancy; depression; other medicines; substance-use history; and access to CBT-I.

SOURCE · 2023 AGS BEERS CRITERIA   SOURCE · FDA SAFETY COMMUNICATION